ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019
Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung).Journal of translational medicine · 2024Pooled it
- Periodontal Disease and Tooth Loss Are Associated with Lung Cancer Risk.BioMed research international · 2020Pooled it
- Trial
- AAV-mediated inner ear gene delivery triggers mild host immune responses in the mammalian inner ear.Molecular therapy. Methods & clinical development · 2025Article
- Inflammation in cancer: therapeutic opportunities from new insights.Molecular cancer · 2025Review
- Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence.Annals of medicine · 2023Review
- Correlation Between Chronic Periodontitis and Lung Cancer: A Systematic Review With Meta-Analysis.Cureus · 2023Review
- Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway.American journal of cancer research · 2023Article
- The role of smoking history in longitudinal changes in C-reactive protein between Black and White older adults in the US.Preventive medicine reports · 2022Article
- Article
- The Protective Anticancer Effect of Natural Lycopene Supercritical COAntioxidants (Basel, Switzerland) · 2022Article
- Potential of Inflammatory Protein Signatures for Enhanced Selection of People for Lung Cancer Screening.Cancers · 2022Article
- Immune response and inflammation in cancer health disparities.Trends in cancer · 2022Review
- Lung cancer screening by volume computed tomography: thriving to high performance.Breathe (Sheffield, England) · 2021Article
- Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small-cell lung cancer.Cancer science · 2021Article
- Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.Med (New York, N.Y.) · 2021Article
- Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.Nature communications · 2019Article
- Management of incidental nodules in lung cancer screening: ready for prime-time?Breathe (Sheffield, England) · 2019Article
- Circulating Inflammation Proteins Associated With Lung Cancer in African Americans.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Article
- The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPreviously, we observed a strong relationship between circulating serum inflammation proteins in relation to lung cancer diagnosis and risk, both in case-control and prospective cohorts. Low-dose computed tomography (LDCT) screening has a high prevalence of false-positive nodules, thus companion noninvasive biomarkers that can distinguish between benign and malignant nodules could have clinical utility and positive impact on patient outcomes.
methodsWe conducted a nested case-control study within the National Lung Screening Trial. Concentrations of 30 inflammation proteins were measured on plasma samples of 262 cases and 528 controls using a highly sensitive and analytically validated electrochemiluminescence V-PLEX immunoassay.
resultsComparing the fourth quartile with the first quartile, we found increased IFNγ and IL12/IL23p40 associated with increased odds of a lung cancer diagnosis [OR 1.89, 95% confidence intervals (CI), 1.16-3.09; OR 2.49, 95% CI, 1.46-4.23, respectively]. Confirming our previous observations, we also detected a relationship between increased IL6, IL8, and C-reactive protein (CRP) with lung cancer diagnosis. These relationships were significant after adjustment for age, gender, race, smoking, body mass index (BMI), family history of lung cancer, and previous diagnoses of inflammatory conditions. However, none of these proteins could distinguish between a benign and malignant lung nodule (IL6: OR 1.25, 95% CI, 0.59-2.64; IL8: OR 1.40, 95% CI, 0.70-2.81; CRP: OR 0.98, 95% CI, 0.45-2.12).
conclusionsWe have discovered new associations for IFNγ and IL12/IL23p40 with lung cancer but have no evidence that these proteins can distinguish between benign and malignant lung nodules. IMPACT: Circulating inflammation proteins are unlikely to have utility as companion LDCT biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.